Citations 999

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma

American Journal of Hematology | January 25, 2019 | Volume: 94 | Issue: 5 | Pages: No page available

10.1002/ajh.25420 | PMID 30680770

Multiple myeloma and kidney transplantation: the beginning of a new era

Clinical Kidney Journal | January 9, 2019 | Volume: 12 | Issue: 2 | Pages: 213-215

10.1093/ckj/sfz003 | PMID 30976398

Outcomes of young patients with Waldenstrom macroglobulinemia (WM).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8609-8609

10.1200/jco.2014.32.15_suppl.8609

Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8608-8608

10.1200/jco.2014.32.15_suppl.8608

Clarifying immunoglobulin gene usage in immunoglobulin light chain amyloidosis by mass spectrometry of amyloid in clinical tissue specimens.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8605-8605

10.1200/jco.2014.32.15_suppl.8605

Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8598-8598

10.1200/jco.2014.32.15_suppl.8598

ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCI–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8600-8600

10.1200/jco.2014.32.15_suppl.8600

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method

American Journal of Hematology | December 28, 2018 | Volume: 94 | Issue: 4 | Pages: 424-430

10.1002/ajh.25391 | PMID 30592078

AbstractTrisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi‐parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near‐tetraploid: 108 (6%). FISH identified trisomies in 82% (621/756) of patients with hyperdiploidy by PCPRO and no trisomy by FISH was observed in 88% (730/834) of patients without hyperdiploidy. 95% (795/834) of patients without hyperdiploidy on PCPRO had one or less trisomy by FISH. Sensitivity and specificity of PCPRO for detecting hyperdiploidy was 86% (621/725) and 84% (730/865), respectively. Sensitivity increased to 94% (579/618) for patients with more than one trisomy. Newly diagnosed MM patients with hyperdiploidy on PCPRO (147/275) had better OS compared to nonhyperdiploid patients (median not reached vs 59 months, P = 0.008) and better progression free survival (median: 33 vs 23 months, P = 0.03). Within the hyperdiploidy group, patients with high‐hyperdiploidy (DNA index: 1.19‐1.50) versus those with low‐hyperdiploidy (DNA index: 1.05‐1.18) had superior OS (3 year OS of 88% vs 68% P = 0.03). Ploidy assessment by flow cytometry can provide rapid, valuable prognostic information and also reduces the number of copy number FISH probes required and hence the cost of FISH.
Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay

Blood | December 13, 2018 | Volume: 133 | Issue: 7 | Pages: 763-766

10.1182/blood-2018-10-875252 | PMID 30545829

Current role of high dose chemotherapy in the management of multiple myeloma

Leukemia & Lymphoma | December 11, 2018 | Volume: 60 | Issue: 6 | Pages: 1349-1351

10.1080/10428194.2018.1533131 | PMID 30526195